Why the study?
To evaluate the impact of a chronic total occlusion in a non-infarct-related artery on clinical outcomes in acute coronary syndrome patients and assess the benefits of staged revascularization.
Does multivessel PCI (staged revascularization) improve clinical outcomes compared to culprit-only PCI in ACS patients with a non-IRA CTO?
Does multivessel PCI (staged revascularization) improve clinical outcomes compared to culprit-only PCI in ACS patients with a non-IRA CTO?
Answers are grounded in this paper and cite their sources.
Successful CTO revascularization in non-infarct-related arteries may provide benefits in ACS patients, particularly in STEMI, though optimal management remains uncertain.
Aim: This systematic review evaluated the impact of a chronic total occlusion (CTO) in a non-infarct-related artery (non-IRA) on clinical outcomes in acute coronary syndrome (ACS) patients and assessed the benefits of staged revascularization.Methods: We performed a comprehensive systematic review to provide further insight into the impact of a CTO in a non-IRA on clinical outcomes after ACS. Moreover, we review the currently available evidence on the clinical significance of staged revascularization for a CTO in a non-IRA patients with ACS and propose whether prophylactic CTO percutaneous coronary intervention (PCI) could improve outcomes in patients who subsequently develop an ACS.Results: Our search identified 999 studies, from which 30 were selected and ten were included in the analysis. The results showed a trend of higher all-cause mortality and major adverse cardiac event rates in the culprit-only-PCI group compared with the multivessel (MV)-PC I group in ST elevation myocardial infarction patients, with varying statistical significance across different outcomes.Conclusion: This review highlights the significant impact of non-IRA CTOs in ACS. Successful CTO revascularization may provide benefits, particularly in ST elevation myocardial infarction, but the optimal management approach remains uncertain. The presence of a non-IRA CTO, especially in cardiogenic shock, predicts worse outcomes. Further research is warranted to determine the effective strategies to improve survival.
No takes yet. Share an insight, caveat, or question.
Sliman et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: